Results 11 to 20 of about 2,116 (170)

Tralokinumab: First Approval [PDF]

Drugs, 2021
Tralokinumab (Adtralza®) is a human IgG4 monoclonal antibody being developed by LEO Pharma for the treatment of atopic dermatitis. The T-helper cytokine IL-13 is thought to play a key role in the pathogenesis of atopic dermatitis. Tralokinumab specifically binds with high affinity to IL-13, inhibiting its interaction with the IL-13 receptor and thereby
Sean Duggan (4873369)
openaire   +3 more sources

Tralokinumab Effectively Disrupts the IL-13/IL-13Rα1/IL-4Rα Signaling Complex but Not the IL-13/IL-13Rα2 Complex

JID Innovations, 2023
Tralokinumab, a fully human mAb specifically targeting the IL-13 cytokine, has demonstrated clinical efficacy and safety in patients with moderate-to-severe atopic dermatitis. Tralokinumab binds IL-13 with high affinity, which prevents the interaction of
Maxim A.X. Tollenaere, Christina Mølck, Ian Henderson, Scott Pollack, Philip Addis, Helle Heibroch Petersen, Hanne Norsgaard   +6 more
doaj   +2 more sources

Tralokinumab in Atopic Dermatitis: A Profile of Its Use

Clinical Drug Investigation, 2022
Tralokinumab (tralokinumab-ldrm) [Adbry™ (USA); Adtralza® (EU)], a human IgG4 monoclonal antibody that binds specifically to interleukin (IL)-13, is an effective and generally well tolerated treatment option for adult patients with moderate to severe atopic dermatitis who are candidates for systemic therapy.
Hannah A. Blair (6846307)
openaire   +3 more sources

Interleukin-13 Inhibitors in the Treatment of Atopic Dermatitis: The Role of Tralokinumab [PDF]

Dermatology Practical & Conceptual
Introduction: The advent of biotechnological drugs has significantly changed the management of atopic dermatitis (AD) and the approach to the moderate-to-severe form of this chronic relapsing disease.
Annunziata Dattola, Martina Tolone, Emanuele Amore, Luigi Bennardo, Simone Amato, Teresa Grieco, Antonio Giovanni Richetta, Giovanni Pellacani, Nevena Skroza, Steven Paul Nisticò   +9 more
doaj   +4 more sources

Therapeutic Potential of Tralokinumab in the Treatment of Atopic Dermatitis: A Review on the Emerging Clinical Data [PDF]

Clinical, Cosmetic and Investigational Dermatology, 2022
Katherine A Kelly,1 Patrick O Perche,1 Steven R Feldman1– 4 1Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA; 2Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC ...
Kelly KA, Perche PO, Feldman SR
doaj   +2 more sources

Docking analysis and the possibility of prediction efficacy for an anti-IL-13 biopharmaceutical treatment with tralokinumab and lebrikizumab for bronchial asthma. [PDF]

PLoS ONE, 2017
Interleukin-13 (IL-13) is associated with allergic airway inflammation and airway remodeling. Our group found a variant with a single nucleotide polymorphism in the IL13 gene at position +2044G>A (rs20541) that was expected to result in the non ...
Yutaka Nakamura, Aki Sugano, Mika Ohta, Yutaka Takaoka   +3 more
doaj   +3 more sources

Successful use of tralokinumab for the treatment of atopic dermatitis on the genitals [PDF]

Journal of Dermatological Treatment
Background Genital involvement in atopic dermatitis(AD) can have a significant impact on the patient’s quality of life. However, inspection of genital areas is not usually conducted during routine examination and patients may be reluctant to inform the ...
Giovanni Paolino, Alessandra Narcisi, Andrea Carugno, Piergiorgio Malagoli, Matteo R. Di Nicola, Antonio Foti, Vittoria G. Bianchi, Andrea Gustavo Locatelli, Paolo Sena, Antonio Costanzo, Santo R. Mercuri, Mario Valenti   +11 more
doaj   +4 more sources

Tralokinumab and Acitretin for the Treatment of Lamellar Ichthyosis

JAMA Dermatology
This case report describes a man in his 30s who presented with severe and generalized congenital ichthyosis and was treated with a combination of tralokinumab and acitretin.
Axel, De Greef, Marie, Baeck
openaire   +3 more sources

Tralokinumab‐related facial redness: a therapeutic challenge

International Journal of Dermatology
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus, eczematous lesions, and lichenification. Treating patients with severe forms of AD is generally challenging for dermatologists. Here, we describe a case of tralokinumab-related facial redness in a patient who had a good response to the drug previously.
Sergio García‐González, Pablo Villagrasa‐Boli, Elena Bularca, Alba Moratiel‐Pellitero, Lucía Prieto‐Torres   +4 more
openaire   +5 more sources

Real-life Case-series Experience with Tralokinumab in Patients with Severe Atopic Dermatitis: When to Consider Tralokinumab?

Journal of Dermatology and Dermatologic Surgery
Atopic dermatitis (AD) is a chronic inflammatory skin condition driven largely by type-2 immune responses, particularly interleukin-13 (IL-13). Tralokinumab, a monoclonal antibody targeting IL-13, has emerged as a novel biologic therapy for moderate-to ...
Fares A. Alkhayal, Ahmed F. Alanazi, Kadi S. Alsubaie   +2 more
doaj   +2 more sources